The market for Anti-CD20 Monoclonal Antibodies (MAbs) is experiencing exponential growth, with key players like Pfizer, Teva, and Aptevo driving the trend.
The Global Anti-CD20 Monoclonal Antibodies (MAbs) Market study, conducted by USD Analytics, provides a comprehensive analysis of the market, covering over 143 pages. The report describes the product and industry scope, market prognosis, and status for 2025-2034. The market is currently expanding, driven by major companies such as Roche, Biogen, Novartis, Genentech, and Amgen.
The market size is estimated to be $12.8 billion in 2025, with a forecasted annual growth rate (CAGR) of 10.2% to reach $30.7 billion by 2034. The market is segmented by type, including Rituximab, Obinutuzumab, Ofatumumab, and biosimilars, and by application, including oncology and autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and lupus.
The report highlights the dominating region as North America and Europe, with Asia-Pacific being the fastest-growing region. Market trends include increased approvals for new indications and improved patient outcomes, driven by expansion into autoimmune markets, biosimilar development, and subcutaneous delivery formats. However, high therapy costs, infusion-related side effects, and biosimilar competition are major challenges.
The report provides an in-depth analysis of market segments, including types and applications, and regional analysis covering North America, South and Central America, Middle East and Africa, Europe, Asia, and Oceania. The report also includes a comprehensive analysis of key manufacturers, including their growth strategies, SWOT analysis, and development plans.
The report’s objectives include analyzing the market’s growth trends, identifying key factors influencing the market, and examining the competitive landscape. The report also includes a five forces and PESTLE analysis, covering political, economic, social, technological, legal, and environmental factors.
Key findings of the report include:
* The global Anti-CD20 Monoclonal Antibodies (MAbs) market is expected to grow at a CAGR of 10.2% from 2025 to 2034.
* The market size is estimated to be $12.8 billion in 2025 and $30.7 billion by 2034.
* North America and Europe are the dominating regions, with Asia-Pacific being the fastest-growing region.
* The market is driven by expansion into autoimmune markets, biosimilar development, and subcutaneous delivery formats.
* High therapy costs, infusion-related side effects, and biosimilar competition are major challenges.
Overall, the report provides a comprehensive analysis of the Global Anti-CD20 Monoclonal Antibodies (MAbs) market, covering market trends, growth drivers, challenges, and key manufacturer analysis.
Zydus Lifesciences Receives US FDA Approval for Generic Version of Absorica, Used to Treat Severe Acne
Zydus Lifesciences has received final approval from the US Food and Drug Administration (USFDA) to launch its isotretinoin capsules in six different strengths. The approval allows the company to produce generic versions of Absorica, a prescription treatment for severe and hard-to-treat forms of nodular acne. The six strengths, ranging from 10 mg to 40 mg, will enable physicians to choose the most suitable dose for each patient’s individual needs.
The isotretinoin capsules will be manufactured at Zydus’ plant in Moraiya, Ahmedabad, ensuring that the product meets global quality standards. This approval marks a significant milestone for the company, which has now received 427 final approvals from the USFDA. Zydus is competing in the US generics market, which is valued at $64.9 billion and growing.
The company has a total of 492 Abbreviated New Drug Application (ANDA) approvals, including 19 tentative approvals, from the USFDA since it started filing in 2003-04. This approval demonstrates Zydus’ commitment to providing affordable skincare solutions to global markets. The company is expanding its product portfolio in dermatology and other critical therapeutic areas, and expects to continue seeking new global partners to help fulfill its mission to supply high-quality products to meet patient needs.
With this approval, Zydus is well-positioned to tap into the growing demand for generic medications in the US market. The company’s commitment to quality and affordability is likely to benefit patients who are in need of effective treatments for severe acne. As Zydus continues to expand its product portfolio and strengthen its partnerships, it is expected to play a significant role in the global generics market. The company’s focus on dermatology and other critical therapeutic areas is also likely to drive growth and innovation in the healthcare industry.
Apollo Hospitals Sees Significant Increase in International Research Recognition
The Apollo Hospitals Group has made significant contributions to global healthcare research, as highlighted in a recent publication in the National Board of Examination Journal of Medical Sciences. The study, “Evaluating a Decade of Research Excellence: A Bibliometric Analysis of Apollo Hospitals Group (2015–2024),” reveals an impressive surge in research publications from Apollo Hospitals, with a growth of over 200% from 255 publications in 2015 to 794 in 2024. The total research output over the decade reached 5,005 publications, demonstrating a consistent and robust dedication to advancing medical knowledge.
The study also highlights the high academic value and impact of Apollo’s research contributions, with an average of 11.9 citations per publication. Furthermore, 26.4% of Apollo’s research involved international collaborations, illustrating the Group’s extensive global research network. The field-weighted citation impact also saw a significant rise from 0.73 in 2015 to 1.88 in 2024, emphasizing the increasing quality and relevance of the research produced by Apollo’s dedicated teams.
The Founder Chairman of Apollo Hospitals Group, Dr. Prathap C. Reddy, emphasized the importance of research in healthcare, stating that it is the cornerstone of progress. He also highlighted the Group’s commitment to promoting higher medical education and training, with over 1,100 postgraduate students being trained across 57 specialties. Dr. Anupam Sibal, Group Medical Director, added that the findings of the bibliometric analysis demonstrate the increasing quality and global relevance of the research emanating from Apollo Hospitals.
The recognition of Apollo Hospitals’ research excellence is a testament to the power of collaborative research and the dedication of its clinical teams to contribute meaningfully to the global medical knowledge base. The publication highlights the importance of investing in structured and collaborative research to drive medical advancements and ultimately enhance patient outcomes. As Dr. Raju Vaishya, Senior Consultant, Orthopaedics, Apollo Hospitals, noted, it is incredibly rewarding to see Apollo Hospitals recognized for its research excellence, and this achievement will further motivate the teams to continue pushing the boundaries of medical science.
Overall, the study demonstrates Apollo Hospitals’ emergence as a leading force in global healthcare research, marked by significant academic output, impactful international collaborations, and a growing influence on medical practices worldwide. The Group’s commitment to research and education is expected to have a positive impact on patient care and outcomes, both in India and globally.
Piramal Pharma supports Women’s Wellbeing with the launch of its i-pill Daily Awareness Initiative
Piramal Consumer Healthcare has launched a new campaign for its i-pill Daily product, which aims to promote women’s health, dignity, and informed choice. The campaign highlights the importance of choosing the right brand, especially in a category where substitution is common and purchases are often made with hesitation. The goal is to encourage consumers to ask boldly, insist clearly, and choose confidently, rather than settling for a substitute due to discomfort or haste.
The campaign is set in a black-and-white style and aims to tackle the barrier of lack of insistence on the right brand at the moment of purchase. The film cleverly draws attention to the outdated discomfort surrounding the buying experience and flips the narrative by urging viewers to ask questions, assert their agency, and choose a trusted brand like i-pill Daily.
According to Nandini Piramal, Chairperson of Piramal Pharma Limited, every woman deserves access to healthcare that is safe, reliable, and respectful of her choices. The campaign reminds women that their health is too important to be left to chance or compromise and encourages them to choose what’s best for them.
Menaka Menon, President and Managing Partner of DDB Mudra Group, commented that the campaign aims to tackle the problem of consumers ending up with a substitute product due to social conditioning and embarrassment around the purchase of a contraceptive product. The campaign plays up the shift in society towards women exercising their discretion and choice, and contrasts it with the meek acceptance typically associated with such decisions in the past.
The campaign is backed by Piramal Pharma’s strong record in women’s wellness and is recognized as one of India’s Most Trusted Brands by Marksmen. It marks a strategic shift from generic awareness to informed, quality-first decisions. The film will be supported across digital platforms, including YouTube and Instagram, and will be amplified on television in select priority markets.
Overall, the campaign aims to empower women to make informed choices about their reproductive health and to choose a trusted brand like i-pill Daily. By encouraging consumers to ask boldly and insist clearly, the campaign hopes to reverse the trend of substitution and promote a culture of confidence and assertiveness around women’s health.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.